|
시장보고서
상품코드
2024511
경카테터 폐동맥판 시장 보고서 : 기술, 원재료, 용도, 최종 사용자, 지역별(2026-2034년)Transcatheter Pulmonary Valve Market Size by Technology, Raw Material, Application, End User, and Region 2026-2034 |
||||||
세계의 경카테터 폐동맥판 시장 규모는 2025년에 1억 280만 달러에 이르렀습니다. 향후, IMARC Group은 2026-2034년 CAGR 7.35%를 나타내, 2034년까지 1억 9,830만 달러에 이를 것으로 예측했습니다. 다양한 심혈관 질환(CVD) 발병률 증가, 활발한 연구개발(R&D) 활동, 고령 인구 증가 등이 시장을 이끄는 주요 요인으로 작용하고 있습니다.
경카테터 폐동맥판은 소, 돼지 또는 사람의 심장 조직으로 만든 인공 판막을 말합니다. 이는 누출되거나 좁아진 폐동맥판을 대체하고 혈류를 개선하기 위해 널리 사용되며, 개흉수술에 비해 절개 부위가 적고 회복이 빠릅니다. 이 밸브는 가늘고 플렉서블 튜브(카테터)를 통해 대혈관에 삽입되어 최소침습(MI) 수술이 이루어집니다. 경카테터 폐동맥판 치환술은 통증이 적고 회복 기간이 짧아 합병증 위험을 줄이면서 증상 개선에 기여합니다. 또한, 혈류를 회복하고 흉통, 호흡곤란, 실신, 피로감 등 대동맥판막 협착증의 징후와 증상을 완화하는 데 도움이 됩니다. 그 결과, 이 밸브는 심장 기형, 폐동맥판 역류, 폐쇄증, 협착증 및 동맥 줄기 이상에 광범위하게 적용되고 있습니다.
경카테터 폐동맥판 시장 동향 :
세계적으로 류마티스성 심장질환, 고혈압성 심장질환, 뇌혈관질환, 염증성 심장질환 등 다양한 심혈관질환(CVD)의 발생률이 증가하고 있는 것이 시장 성장을 이끄는 주요 요인 중 하나입니다. 이에 따라 고령 인구 증가와 중증 대동맥판막 협착증, 승모판막 역류증, 삼첨판막 역류증과 관련된 퇴행성 질환의 유병률 증가가 시장 성장을 견인하고 있습니다. 또한, 소아 경카테터 폐동맥판 치료의 제품 보급이 시장 성장에 기여하고 있습니다. 이는 주로 폐동맥 협착증, 폐쇄증, 패혈증 및 기타 관련 질환의 발생 빈도가 증가함에 따라 효과적인 치료 옵션으로 제품 채택을 촉진하고 있습니다. 이와 더불어, 경카테터 폐동맥판 치환술(TPVR)에 인공지능(AI)을 통합하여 수술 전 계획 수립, 위험 요소 식별, 진단 및 임상적 의사 결정 개선에 기여하면서 시장 성장에 박차를 가하고 있습니다. 또한, 풍선 확장 기술에 대한 수요 증가도 시장 성장에 긍정적인 영향을 미치고 있습니다. 이 기술은 보다 빠르고 간편한 프로세스를 수반하며 높은 정밀도와 정확한 결과를 가져다주기 때문입니다. 또한, 니티놀로 제작되어 밸브의 정확한 위치 배치를 가능하게 하고, 정위치로 전개되는 것을 보장하는 자가 확장형 상륜부 대동맥 판막 시스템인 '하이드라 대동맥 판막'의 출시도 시장 성장에 힘을 보태고 있습니다. 기타, 혁신적인 심장 판막에 대한 수요 증가, 고혈압 환자 수 증가, 의료 산업의 급격한 성장, 소비자 지출 능력 향상, 광범위한 연구개발(R&D) 활동, 효율적인 경카테터 폐동맥판 개발을 위한 다양한 정부 주도 이니셔티브의 시행 등 다양한 요인들이 시장 전망을 밝게할 것으로 예측됩니다. 시장 전망을 밝게할 것으로 예측됩니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문 :
- 지금까지 세계의 경카테터 폐동맥판 시장은 어떤 추세를 보였으며, 향후 몇 년 동안 어떤 추세를 보일까요?
- 세계의 경카테터 폐동맥판 시장 성장 촉진요인, 제약 요인 및 기회는?
- 주요 지역 시장은?
- 어떤 국가가 가장 매력적인 경카테터 폐동맥판 시장을 형성하고 있는가?
- 기술별 시장 현황은?
- 원재료별 시장 현황은?
- 용도에 따른 시장 내역은?
- 최종 사용자별 시장 분석은 어떻게 이루어지고 있는가?
- 세계의 경카테터 폐동맥판 시장 경쟁 구도는 무엇인가?
- 세계 경카테터 폐동맥판 시장의 주요 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 경카테터 폐동맥판 시장
제6장 시장 분석 : 기술별
제7장 시장 분석 : 원재료별
제8장 시장 분석 : 용도별
제9장 시장 분석 : 최종 사용자별
제10장 시장 분석 : 지역별
제11장 성장 촉진요인, 억제요인 및 기회
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KTH 26.05.15The global transcatheter pulmonary valve market size reached USD 102.8 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 198.3 Million by 2034, exhibiting a growth rate (CAGR) of 7.35% during 2026-2034. The increasing incidence of various cardiovascular diseases (CVDs), extensive research and development (R&D) activities, and the rising geriatric population represent some of the key factors driving the market.
A transcatheter pulmonary valve refers to an artificial valve made from cow, pig, or human heart tissue. It is widely used to replace leaky or narrowed pulmonary valves to improve blood flow, with fewer incisions and faster recovery than open surgery. These valves are inserted through a thin, flexible tube (catheter) into a large blood vessel involving a minimally invasive (MI) procedure. Transcatheter pulmonary valve replacement involves less pain and a shorter recovery period and helps in improving symptoms while lowering the risk of medical complications. It also helps to restore blood flow and reduce the signs and symptoms of aortic valve stenosis, such as chest pain, shortness of breath, fainting, and fatigue. As a result, these valves find extensive applications in cardiac anomaly, pulmonary regurgitation, atresia, stenosis, and truncus arteriosus.
Transcatheter Pulmonary Valve Market Trends:
The rising incidences of various cardiovascular diseases (CVDs), such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases across the globe, are among the key factors driving the market growth. In line with this, the rising geriatric population and increasing prevalence of degenerative abnormalities associated with severe aortic stenosis and mitral and tricuspid regurgitation are favoring the market growth. Moreover, the widespread product adoption in the treatment of pediatric transcatheter pulmonary is contributing to the market growth. This can be primarily attributed to the increasing frequency of pulmonary stenosis, atresia, tetralogy of Fallot, and other related disorders, which is facilitating the product adoption as an effective treatment option. Apart from this, the integration of artificial intelligence (AI) in the transcatheter pulmonary valve replacement (TPVR) procedure, as it assists in pre-procedural planning, identifying risk factors, and enhancing diagnosis and clinical decision-making, is providing an impetus to the market growth. Additionally, the increasing demand for balloon-expanded technology as it involves a faster and simpler process and offers high accuracy and precision of the result is positively influencing the market growth. Besides this, the launch of the hydra aortic valve, which is a self-expanding supra-annular aortic system made of nitinol that allows precise placement of the valve and ensures orthotopic deployment, is propelling the market growth. Other factors, including growing demand for innovative heart valves, an increasing number of hypertension cases, escalating growth in the healthcare industry, rising expenditure capacities of consumers, extensive research and development (R&D) activities, and the implementation of various government initiatives to develop efficient transcatheter pulmonary valves, are anticipated to create a positive outlook for the market.
Key Market Segmentation:
This report provides an analysis of the key trends in each segment of the global transcatheter pulmonary valve market, along with forecasts at the global, regional, and country level from 2026-2034. The report has categorized the market based on technology, raw material, application, and end user.
Technology Insights:
- Balloon-Expanded Transcatheter Valve
- Self-Expanded Transcatheter Valve
Raw Material Insights:
- Tissue Engineered
- Synthetic
Application Insights:
- Tetralogy of Fallot
- Cardiac Anomaly
- Pulmonary Atresia
- Pulmonary Stenosis
- Pulmonary Regurgitation
- Truncus Arteriosus
- Others
End User Insights:
- Adult
- Pediatric
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others);Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for transcatheter pulmonary valve. Some of the factors driving the North America transcatheter pulmonary valve market included the rising geriatric population, growing demand for innovative heart valves, and various technological advancements.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global transcatheter pulmonary valve market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Artivion Inc., Boston Scientific Corporation, Braile Biomedica, Colibri Heart Valve LLC, Edwards Lifesciences Corporation, JenaValve Technology Inc., Labcor Laboratorios Ltda., Medtronic plc, Venus Medtech (Hangzhou) Inc., etc.
Key Questions Answered in This Report:
- How has the global transcatheter pulmonary valve market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global transcatheter pulmonary valve market?
- What are the key regional markets?
- Which countries represent the most attractive transcatheter pulmonary valve markets?
- What is the breakup of the market based on technology?
- What is the breakup of the market based on the raw material?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What is the competitive structure of the global transcatheter pulmonary valve market?
- Who are the key players/companies in the global transcatheter pulmonary valve market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Transcatheter Pulmonary Valve Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Technology
- 6.1 Balloon-Expanded Transcatheter Valve
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Self-Expanded Transcatheter Valve
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Raw Material
- 7.1 Tissue Engineered
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Synthetic
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Application
- 8.1 Tetralogy of Fallot
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Cardiac Anomaly
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Pulmonary Atresia
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Pulmonary Stenosis
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Pulmonary Regurgitation
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Truncus Arteriosus
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
- 8.7 Others
- 8.7.1 Market Trends
- 8.7.2 Market Forecast
9 Market Breakup by End User
- 9.1 Adult
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Pediatric
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 Drivers, Restraints, and Opportunities
- 11.1 Overview
- 11.2 Drivers
- 11.3 Restraints
- 11.4 Opportunities
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Artivion Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Boston Scientific Corporation
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Braile Biomedica
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Colibri Heart Valve LLC
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Edwards Lifesciences Corporation
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 JenaValve Technology Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Labcor Laboratorios Ltda.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 Medtronic plc
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Venus Medtech (Hangzhou) Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.1 Abbott Laboratories
